{
  "abstract": "Trophoblast cell surface antigen 2 (TROP-2) is a transmembrane glycoprotein involved in intracellular signaling pathways that regulate cancer proliferation, invasion, and survival. TROP-2 is minimally expressed in normal tissues but widely overexpressed in epithelial malignancies, including breast, lung, pancreatic, bladder, and gynecologic cancers. Notably, high levels of TROP-2 RNA and protein expression have been reported in endometrial, ovarian, and cervical cancers, supporting its role in tumor progression and its potential value as a therapeutic target. Recent developments have identified TROP-2 as a promising target for antibody-drug conjugates (ADC)s, particularly in advanced or recurrent gynecologic malignancies where therapeutic resistance remains a major clinical challenge. Although immunotherapy, Poly (ADP-ribose) polymerase (PARP) inhibitors and chemotherapy have shown efficacy in subsets of patients, a significant unmet need persists, especially in those previously treated with platinum-based regimens and immune checkpoint inhibitors. Encouraging preclinical data and early-phase clinical trials have prompted the investigation of several anti-TROP-2 ADCs, including sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan. These agents leverage the selective expression of TROP-2 on tumor cells to deliver cytotoxic payloads, while also demonstrating a bystander effect that extends activity to antigen-negative cells. Their clinical application is currently being explored in gynecologic settings. In this review, we provide an overview of TROP-2’s biological role and its relevance as a prognostic and predictive biomarker in gynecologic cancers. We further summarize the available clinical data on TROP-2-targeting ADCs and discuss future perspectives for integrating these agents into therapeutic strategies aimed at improving outcomes in ovarian, endometrial, and cervical cancers.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "Review",
  "arxiv": null,
  "author_total": 16,
  "authors": [
    {
      "name": "Erica Perri"
    },
    {
      "name": "Maria Rosaria Lamia"
    },
    {
      "name": "Carmela Pisano"
    },
    {
      "name": "Sabrina Chiara Cecere"
    },
    {
      "name": "Marilena Di Napoli"
    },
    {
      "name": "Lorenzo Lobianco"
    },
    {
      "name": "Sabrina Rossetti"
    },
    {
      "name": "Rosa Tambaro"
    },
    {
      "name": "Jole Ventriglia"
    },
    {
      "name": "Chiara D’Alessio"
    },
    {
      "name": "Elisabetta Coppola"
    },
    {
      "name": "Emilia Scarpa"
    },
    {
      "name": "Giovanni Pacifico"
    },
    {
      "name": "Vincenzo Terrano"
    },
    {
      "name": "Sandro Pignata"
    },
    {
      "name": "Anna Passarelli"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1rx0ejnbtc7ar.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.2005008",
  "fulltext_url": null,
  "id": "1rx0ejnbtc7ar",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.2005008",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "feed-journal",
      "medicine/oncology"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-09",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/1rx0ejnbtc7ar.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T18:20:20Z",
      "native_id": "10.3389/fonc.2026.2005008",
      "source": "feed-frontiers",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.2005008"
    },
    {
      "first_seen": "2026-11-10T00:21:42Z",
      "native_id": "10.3389/fonc.2026.2005008",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.2005008/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "feed-journal:medicine/oncology",
      "subfield": "oncology"
    }
  ],
  "title": "Emerging trophoblast cell-surface antigen 2-targeting antibody-drug conjugates in gynecological cancers",
  "title_text": "Emerging trophoblast cell-surface antigen 2-targeting antibody-drug conjugates in gynecological cancers",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T00:21:42Z",
  "url": "https://research.draconitic.com/paper/1rx0ejnbtc7ar",
  "venue": "Frontiers in Oncology",
  "versions": []
}